[1]Jacot W, Im SA, Loi S, et al. Exploratory biomarker analysis of Trastuzumab deruxtecan (TDXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic brea...
近期，一项研究[3]评估了ADC药物相比其他HER2靶向疗法针对HER2阳性局部晚期或转移性乳腺癌患者的生存获益，结果表明，ADC带来的无进展生存期（PFS）和总生存期（OS）改善具有统计学显著性，尤其是针对既往接受过抗HER2治疗的患者，再次验证了ADC药物在HER2阳性晚期乳腺癌中的治疗价值。现将研究主要内容梳理如下，以飨读者...
X.; Mao, C.; Fan, Q.; Bai, Y.; Ba, Y.; et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021, 24, 913–925. ...
A new Neu—a syngeneic model of spontaneously metastatic HER2-positive breast cancerMetastatic disease results from the dissemination of tumor cells beyond their organ of origin to grow in distant organs and is the primary cause of death in patients with advanced breast cancer. Preclinical murine ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
在过去 HER2靶向治疗成果的基础上,对这些新概念的研究和这些方法的使用将最终导致持续的进展。 参考文献:1.Sandra M. Swain, Mythili Shastry & Erika Hamilton Targeting HER2-positive breast cancer: advances and future directions Nature Reviews Drug Discovery(2022)...
Janjigian在Nature上发表题为The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer 的文章,招募了434位HER2呈阳性,并患有胃肠道恶性肿瘤的病人,以随机双盲原则,进行PD-1抗体药物与曲妥珠单抗和化疗联合用药(clinicaltrials.gov, NCT03615326),并发现此种干预方式相比较传统的...
[10]Gullo G,Bettio D,Torri V,Masci G,Salvini P,Santoro A.Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.Investig N Drugs.2009;27:179–83. ...
M. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer 7, 56 (2021). Article CAS PubMed PubMed Central Google Scholar Coussens, L. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene...
HER-2 是一种跨膜生长因子受体,由人类的HER2/neu基因编码,与 HER1 (EGFR)、HER3 和 HER4 一起属于 HER 家族蛋白。EGF 相关的生长因子中的任何一个与 HER1、HER3 或 HER4 结合会诱导HER受体二聚化,随后激活酪氨酸激酶胞内结构域,从而触发许多不同的下游途径。[1] ...